Eiger BioPharmaceuticals Inc (EIGRQ)

[Fezziwig2008]

EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.” https://www.google.com/amp/s/www.the-scientist.com/news-opinion/seeking-an-early-covid-19-drug-researchers-look-to-interferons-67753/amp